medical therapy of prostate symptoms (mtops) jeannette y. lee, ph.d. university of alabama at...
TRANSCRIPT
![Page 1: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/1.jpg)
Medical Therapy of Prostate Medical Therapy of Prostate Symptoms (MTOPS)Symptoms (MTOPS)
Jeannette Y. Lee, Ph.D.Jeannette Y. Lee, Ph.D.University of Alabama at University of Alabama at
BirminghamBirmingham
![Page 2: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/2.jpg)
Benign Prostatic Hyperplasia (BPH)Benign Prostatic Hyperplasia (BPH)
• Common cause of morbidity among older men
• Characterized by bothersome lower urinary tract symptoms (LUTS)
• Men with BPH and larger prostates due to BPH are at increased risk of complications such as acute urinary retention
![Page 3: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/3.jpg)
PrevalencePrevalence
• Clinical Significant BPH– AUA symptom score > 7 points (moderate to
severe lower urinary tract symptoms)– Depressed peak uroflow (< 15 mL/sec)
• Prevalence by age group– 17% in men from 50-59 yrs of age– 27% in men from 60-69 yrs of age– 35% in men from 70-79 yrs of age
![Page 4: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/4.jpg)
MTOPS Trial DesignMTOPS Trial Design
• Randomized, double blind, 2 x 2 factorial
• Two-year enrollment period
• Minimum four-year follow-up period
• Objective: to determine if doxazosin or finasteride, alone or in combination delayed or prevented clinical progression of BPH
![Page 5: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/5.jpg)
Inclusion CriteriaInclusion Criteria
• Men > 50 yrs of age
• AUA symptom score of 8-35
• Peak urinary flow rate of 4-15 ml/sec
• Voided volume > 15 ml
![Page 6: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/6.jpg)
Exclusion CriteriaExclusion Criteria
• Prior medical or surgical intervention for BPH
• Supine blood pressure < 90/70 mmHg
• PSA > 10 ng/ml
![Page 7: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/7.jpg)
Factorial DesignFactorial Design
Finasteride
+
Doxazosin
Finasteride
Doxazosin Placebo
![Page 8: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/8.jpg)
TreatmentsTreatments
• 5- reductase inhibitor Finasteride dose: 5 mg
• Alpha blocker Doxazosin dose doubled weekly starting with 1 mg daily until daily dose of 8 mg reached.
![Page 9: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/9.jpg)
Follow-up EvaluationsFollow-up Evaluations
• Vital signs
• AUA symptom score
• Urinary flow rate
• Adverse Events
• DRE, serum PSA< urinalysis
• Prostate volume (TRUS)
![Page 10: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/10.jpg)
Follow-up QuestionnaireFollow-up Questionnaire
• AUA Symptom Score
• QOL Short Form-36 (SF-36)
• Sexual function questionnaire
• Prostatitis Questionnaire
![Page 11: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/11.jpg)
Primary EndpointsPrimary Endpoints
• Primary endpoint: time to BPH progression defined as– > 4 point increase in AUA symptom score– Acute urinary retention– Renal insufficiency – Recurrent urinary tract infection– Urinary incontinence
![Page 12: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/12.jpg)
Secondary EndpointsSecondary Endpoints
• Changes over time – AUA symptom score – Maximal urinary flow rate– PSA level– Prostate volume
• Cumulative incidence of invasive treatments for BPH
![Page 13: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/13.jpg)
ResultsResults
• 3047 men randomized• Baseline characteristics
– Mean age: 62.6 yrs– White: 82%– Mean AUA symptom score: 16.9– Mean prostate volume: 36.3 ml– Mean Max urinary flow rate: 10.5 ml/min– Mean post void residual volume: 68.1 ml– Mean serum PSA: 2.4 ng/ml– Mean serum creatinine: 1.1 mg/dl
![Page 14: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/14.jpg)
Clinical Progression of BPHClinical Progression of BPHRate per 100 PYsRate per 100 PYs
Placebo
(N=737)
Doxazosin
(N=756)
Finasteride
(N=768)
Combination
(N=786)
Clinical
Prog.
4.5 2.7 2.9 1.5
> 4 pt rise
AUASS
3.6 1.9 2.5 1.3
AUR 0.6 0.4 0.2 0.1
Incont. 0.3 0.3 0.3 0.1
![Page 15: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/15.jpg)
Clinical Progression of BPHClinical Progression of BPHEventsEvents
Placebo
(N=737)
Doxazosin
(N=756)
Finasteride
(N=768)
Combination
(N=786)
Clinical
Prog.
122 73 78 42
> 4 pt rise
AUASS
97 55 65 36
AUR 18 9 6 4
Incont. 6 7 7 1
UTI 1 2 0 1
![Page 16: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/16.jpg)
Cumulative Incidence of ProgressionCumulative Incidence of Progression(N Engl J Med 2003: 349 (25): 2387-97)(N Engl J Med 2003: 349 (25): 2387-97)
![Page 17: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/17.jpg)
Rate of Progression per 100 PYsRate of Progression per 100 PYs
• Placebo: 4.5 BPH Progressors
• Doxazosin: 2.7 BPH Progressors
• Finasteride: 2.9 BPH Progressors
• Combination: 1.5 BPH Progressors
![Page 18: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/18.jpg)
Invasive Therapy due to BPHInvasive Therapy due to BPH
Cumulative Placebo
(N=737)
Doxazosin
(N=756)
Finasteride
(N=768)
Combination
(N=786)
Rate per 100 PY
1.3 1.3 0.5 0.4
Events 37 26 14 12
![Page 19: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/19.jpg)
Adverse Events – Sexual FunctionAdverse Events – Sexual Function(Rate per 100 PYs)(Rate per 100 PYs)
Placebo
(N=737)
Doxazosin
(N=756)
Finasteride
(N=768)
Combination
(N=786)
Erectile dysfunction
3.32 3.56 4.53* 5.11*
Decreased libido
1.4 1.56 2.36* 2.51*
Abnormal ejaculation
0.83 1.10 1.78* 3.05*
* p<0.05 compared to placebo
![Page 20: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/20.jpg)
Adverse Events – HypotensionAdverse Events – Hypotension(Rate per 100 PYs)(Rate per 100 PYs)
Placebo
(N=737)
Doxazosin
(N=756)
Finasteride
(N=768)
Combination
(N=786)
Dizziness 2.29 4.41* 2.33 5.35*
Postural hypotension
2.29 4.03* 2.56 4.33*
Asthenia 2.06 4.08* 1.56 4.20*
* p<0.05 compared to placebo
![Page 21: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/21.jpg)
MTOPS SummaryMTOPS Summary
• Combination therapy with doxazosin and finasteride was safe and reduced the risk of overall clinical progression more than each drug alone.
• Finasteride containing regimens reduced the long-term risk of AUR and need for invasive therapy.
McConnell et al, N Engl J Med 2003.
![Page 22: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/22.jpg)
Methods papersMethods papers
• Study Design – Bautista et al, Controlled Clinical Trials 2003
• Recruitment– Kusek et al, Controlled Clinical Trials 2002
![Page 23: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/23.jpg)
Secondary AnalysesSecondary Analyses
• Placebo patients – baseline factors associated with clinical progression *– Total prostate volume– PSA– Peak flow rate– Post residual volume– Age
* Crawford et al, J Urol 2006
![Page 24: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/24.jpg)
Secondary AnalysesSecondary Analyses
• Combination therapy is better than either agent alone (finasteride, doxazosin) in decreasing the risk of clinical BPH progression in those with higher prostate volumes*
Kaplan et al, J Urol 2006
![Page 25: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/25.jpg)
MPSAMPSA
• MTOPS Prostatic Sample Analysis Consortium – evaluate biomarkers associated with BPH (Mullins et al, J Urol 2008).
![Page 26: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/26.jpg)
Analyses in ProgressAnalyses in Progress
• Longitudinal analyses of sexual function
• Risk of prostate cancer
![Page 27: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/27.jpg)
MTOPS Data AvailableMTOPS Data Available
• Uroflow Measurements (quarterly)
• Compliance/pill counts (quarterly)
• PSA measurements (semi-annually)
• PE, CBC, serum chemistry, urinalysis (annually)
• TRUS and Biopsy (Screening, 12 mos, end of study)
![Page 28: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/28.jpg)
MTOPS QuestionnairesMTOPS Questionnaires
• AUA Symptom Questionnaire (quarterly)
• Sexual Function Questionnaire (screening and end of study)
• Medical Outcomes Study (MOS) – Short Form 36 (SF-36) (annually)
• Prostatitis Questionnaire (annually)
![Page 29: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/29.jpg)
MTOPS Data from Diagnostic MTOPS Data from Diagnostic CenterCenter
• PSA (ng/ml)
• LH (mIU/ml)
• Testosterone (ng/dl)
• % Free PSA
• Total PSA
![Page 30: Medical Therapy of Prostate Symptoms (MTOPS) Jeannette Y. Lee, Ph.D. University of Alabama at Birmingham](https://reader030.vdocuments.us/reader030/viewer/2022032706/56649dde5503460f94ad671e/html5/thumbnails/30.jpg)
MTOPS Samples in NIDDK MTOPS Samples in NIDDK RepositoryRepository
Type of Specimen
Number Number of participants
Serum 102,916
(0.5 ml aliquots)
4127
Frozen tissue 7001
Bx samples
1449
Fixed tissue 14,416
Bx blocks
1449